1. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital
- Author
-
Gemma Navarro, M. Cervantes, Oriol Gasch, Aina Gomila, M L Machado, E Prieto, E Van den Eynde, J Oristrell, J C Oliva, L Falgueras, S Calzado, S Ortonobes, A Morón, Silvia Capilla, and M. Navarro
- Subjects
Male ,0301 basic medicine ,Microbiology (medical) ,2019-20 coronavirus outbreak ,Pediatrics ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,030106 microbiology ,Antibodies, Monoclonal, Humanized ,Methylprednisolone ,tocilizumab ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Tocilizumab ,severe pneumonia ,medicine ,Corticosteroids ,Humans ,In patient ,Hospital Mortality ,030212 general & internal medicine ,skin and connective tissue diseases ,Aged ,Retrospective Studies ,General Immunology and Microbiology ,In hospital mortality ,business.industry ,COVID-19 ,Retrospective cohort study ,General Medicine ,Middle Aged ,medicine.disease ,mortality ,Hospitals ,humanities ,COVID-19 Drug Treatment ,respiratory tract diseases ,body regions ,Pneumonia ,Infectious Diseases ,chemistry ,Spain ,Original Article ,Female ,business ,Research Article ,medicine.drug - Abstract
Background There is an urgent need to reduce mortality of COVID-19. We examined if corticosteroids and tocilizumab reduce risk for death in patients with severe pneumonia caused by SARS-CoV-2. Methods A retrospective cohort study was performed in a single university hospital. All adult patients admitted with confirmed severe COVID-19 pneumonia from 9 March to 9 April 2020 were included. Severe pneumonia was defined as multi-lobar or bilateral pneumonia and a ratio of oxygen saturation by pulse oximetry to the fraction of inspired oxygen (SpFi)
- Published
- 2021
- Full Text
- View/download PDF